Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 255-258

  Rajagopalan, Kumar ^a   Peereboom, David ^a,b   Budd, G Thomas ^a,b   Olencki, Thomas ^a,b   Murthy, Siva ^a   Elson, Paul ^b   McLain, Denise ^b   Bukowski, Ronald ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

FUDR; Hormone refractory metastatic prostate cancer

Indexed keywords

FLOXURIDINE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CENTRAL VENOUS CATHETER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; HUMAN; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; CIRCADIAN RHYTHM; FLOXURIDINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0032414468     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006195815320     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998
2. Torti FM, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe L, Freiha FS: Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1: 477-482, 1983
3. Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and practice of oncology. 4th ed. Lippincott, 1993, p. 1107
4. Clarkson B, O'Connor A, Winston L, Hutchison D: The physiologic disposition of 5-FU and 5-flouro-2-deoxyuridine in man. Clin Pharmacol Ther 5: 581-610, 1964
5. Chabner BA: Pyrimidine antagonists. In Chabner BA (ed) Pharmacologic Principles of Cancer Therapy. WB Saunders, Philadelphia, 1982, pp 183-212
6. Lokich JJ, Sonneborn H, Paul S, Zipoli T: Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy. Cancer Treat Rep 67: 791-793, 1983
7. Daher GC, Zhang RW, Soong SJ, Diasio RB: Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: Possible relevance to 5-fluorodeoxyuridine chemotherapy. Drug Metab Dispos 19: 285-287, 1991
8. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990
9. Von Roemeling R, Hrushesky WJM: Determination of the therapeutic index of fluxuridine by its circadian infusion pattern. J Natl Cancer Int 82: 386-393, 1990
10. Hrushesky WJM, Von Roemeling R, Fraley EE, Rabatin JT: Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol 4: 110-115, 1998
11. Von Roemeling R, Hrushesky WJM: Circadian patterning of continuous Floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 7: 1710-1719, 1989
12. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11(8): 1566-1572, 1993
13. Kelly WK, Scher M, Mazumdar M, Schwartz M, Vlamis V: Prostate specific antigen (PSA) as a measure of disease outcome in metastatic hormone refractory prostate cancer (PC). Proc Am Soc Clin Oncol 11: 199, 1992
14. Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP: The continued evaluations of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116: 211-213, 1976
15. Murphy GP, Priore RL, Scardino PT: Hormone refractory metastatic prostate cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-flourouracil plus cyclophosphamide. Urol 32: 33-40, 1988
16. Tannock IF, Osaba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996
17. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P: Intrahepatic or systemic infusion of flouordeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107: 459-465, 1987
18. Kuzel MK, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, Kozlowski J, Vozelgang NJ, Blough R, Benson AB: A phase II study of continuous infusion 5-fluoruracil in advanced hormone refractory prostate cancer. Cancer 72(6): 1965-1968, 1993
19. Von Roemeling R, Fisher H, DeConti R, Horton J, Wilbur H, Hrushesky W, Ruckdeschel J: Continuous FUDR infusion of hormone refractory prostate cancer. A phase I/II study. Proc Am Soc Clin Oncol 10: 171, 1991
20. Ohmori H, Matsumura Y, Ochi J, Kobashi K, Akebi N, Saika T, Nanba K, Tanahashi T, Josen T, Nasu Y: Phase II study of 5′-DFUR treatment of the bladder and prostate cancer. Jap J Cancer Chemother 18(13): 2307-2314, 1991
21. Sampaio C, Olencki T, Murthy S, Budd GT, McLain D, Lorenzi V, Tuason L, Bukowski RM: Phase II trial of circadian infusion of the antimetabolite floxuridine in patients with metastatic renal cell carcinoma. J Infus Chemother 4(2): 100-103, 1994